Psychedelic Assisted Therapies

Ultra-Low-Dose Ketamine May Offer Relief For Opioid Withdrawal, Study Finds
Clearmind Medicine Files International Patent For Ibogaine Combination Therapy
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
Clearmind Medicine Files International Patent For Ibogaine Combination Therapy
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
Biden Administration Finalizes Rule To Expand Mental Health Care Access: How This Could Impact The Psychedelics Industry
Incannex Secures $60M Financing To Drive Advances In Psychedelic And Cannabinoid Therapies

Psychedelic Assisted Therapies Recent News

Athletes Embrace Psychedelic Therapy For Concussion Symptoms, More Than One-Third Say It Helps
Psychedelic Therapy Needs To Move Beyond Mystical Experiences, Say Researchers In New Study
Explore new insights into the therapeutic potential of psychedelics beyond mystical experiences and their impact on clinical outcomes.
Single-Dose Psilocybin Therapy Shows Promise For Treating Alcohol Use Disorder, Study Finds
New study shows single-dose psilocybin therapy may reduce alcohol consumption in alcohol use disorder patients, offering a promising new treatment approach.
FDA Sets September Meeting To Discuss Psychedelic And Other Treatments For PTSD
FDA schedules public meeting to discuss potential psychedelic treatments for PTSD, inviting input from veterans, advocates and researchers
Could Psychedelics End Binge Drinking? A Breakthrough Patent Says Yes
Clearmind Medicine secures a U.S. patent for its MEAI-based binge behavior treatment, marking a significant advancement in addressing Alcohol Use Disorder.
Psychedelics Enhance Creativity After Use, But MDMA Disrupts Memory, Study Shows
New research reveals distinct cognitive effects of psychedelics and MDMA, showing that psychedelics may impair focus but boost creativity, while MDMA primarily disrupts memory.
DEA Faces Legal Challenge Over Denial Of Psilocybin For End-Of-Life Care
A federal appeals court hears a critical case on whether the DEA must allow psilocybin use for terminally ill patients under Right to Try laws
Colorado's Psilocybin Industry Takes Off: New Rules For Magic Mushroom Businesses
In milestone move, Colorado finalizes psilocybin industry rules, creating a framework for licensed businesses and supervised therapy centers.
Gov Healy Signs HERO Act, Establishing Psychedelics Working Group For Massachusetts Veterans
Massachusetts Governor signs HERO Act, establishing a working group to study the potential of psychedelics like psilocybin and MDMA in treating veterans' mental health.
FDA Poised To Make Historic Decision On MDMA Therapy To Treat PTSD: Here's How Things Stand
The FDA is set to decide on MDMA therapy for PTSD, a move that could revolutionize treatment for veterans and others with severe trauma. Here's what's at stake
FDA Clears Incannex To Proceed With Phase 2 Psilocybin-Assisted Therapy Trial For Anxiety
FDA approves Incannex's Phase 2 trial for psilocybin-assisted psychotherapy in treating generalized anxiety disorder, following a successful review of the IND application.